Shares of BIOCYTOGEN-B (02315) surged more than 16%. At the time of writing, the stock was up 14.57% to HK$46.4, with a turnover of HK$94.806 million.
The significant move follows the company's recent recognition at a major industry event held in Tianjin on June 26-27, where the "2026 China's Top 100 Pharmaceutical Innovation Companies" list was unveiled. BIOCYTOGEN was once again included in the ranking and ascended to the top tier. This elevation reflects the industry's growing acknowledgment of the company's comprehensive capabilities in technological innovation, drug research and development, intellectual property strategy, and the translation of innovative outcomes into value. It signifies that the company is transitioning from a phase of continuous accumulation in technology and platform capabilities to a new stage focused on the large-scale development of innovative assets and the global realization of their value.
In a related development this May, BIOCYTOGEN officially launched its new-generation, AI-driven antibody discovery platform, RenSuper Workstation. This platform represents a significant upgrade, building upon the company's foundational RenMice® fully human antibody technology and the extensive resources accumulated through its "Thousand Mice Ten Thousand Antibodies" project. It further solidifies the company's innovative edge in the field of primary antibody discovery.
Leveraging a repository of authentic, fully human antibody sequences covering over 1,000 potentially druggable targets, the RenSuper Workstation integrates large-scale experimental data, artificial intelligence analysis, and high-throughput automation capabilities. This integration is driving the evolution of antibody discovery from the traditional "customized project" model towards a new paradigm characterized as "searchable, scalable, and more efficient."
Comments